July 10th, 2012

FDA Panel Supports Continued Testing of Pain Drugs

By

A panel of arthritis experts recommended Monday that the federal government allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure. The Food and Drug Administration's 21-member panel of arthritis experts voted unanimously that research on the nerve-blocking drugs should continue, with certain safety precautions. Reports of joint failure led the agency to halt studies of the drugs in 2010 before any of the medications could be submitted for U.S. approval…"There's clearly a worrisome safety signal, but in spite of that, I think there's an unmet need in certain patient populations," said panelist Dr. Sherine Gabriel, of the Mayo Medical School in Rochester, Minn.

Additional coverage: FederalNewsRadio, HealthDay,

 

AP by Matthew Perrone

Tags: Dr. Sherine Gabriel, Food and Drug Administration, Innovation (Center of), Mayo Clinic Rochester

Contact Us · Privacy Policy